Cogent Biosciences, Inc.

NasdaqGS:COGT Stok Raporu

Piyasa değeri: US$991.9m

Cogent Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Andy Robbins

İcra Kurulu Başkanı

US$7.9m

Toplam tazminat

CEO maaş yüzdesi8.3%
CEO görev süresi4.1yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi4.3yrs

Son yönetim güncellemeleri

Recent updates

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Sep 04
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences: Inflection Year Directly Ahead

Jun 23

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

May 22
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst

Feb 14

Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 27
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 20
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Mar 05
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 18
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Cogent Biosciences: What's Ahead

Sep 13

Cogent Biosciences: APEX Data Was Interesting, But We Need More

Jun 26

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 10
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Cogent Biosciences names new chief legal officer

May 03

What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Mar 17
What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Cogent Biosciences gets Piper Sandler nod on Kiq acquisition

Dec 23

Cogent Biosciences prices upsized $100M equity offering

Dec 02

Cogent Bio launches $60M equity offering, shares down 7%

Nov 30

Cogent Bio reports data from PLX9486 combo trial in GIST patients

Nov 18

Cogent Biosciences EPS misses by $4.91

Nov 09

CEO Tazminat Analizi

Andy Robbins'un ücretlendirmesi Cogent Biosciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$242m

Jun 30 2024n/an/a

-US$227m

Mar 31 2024n/an/a

-US$212m

Dec 31 2023US$8mUS$656k

-US$192m

Sep 30 2023n/an/a

-US$178m

Jun 30 2023n/an/a

-US$157m

Mar 31 2023n/an/a

-US$148m

Dec 31 2022US$4mUS$624k

-US$140m

Sep 30 2022n/an/a

-US$126m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$3mUS$593k

-US$72m

Sep 30 2021n/an/a

-US$163m

Jun 30 2021n/an/a

-US$194m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$18mUS$102k

-US$179m

Tazminat ve Piyasa: Andy 'nin toplam tazminatı ($USD 7.90M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.19M ).

Tazminat ve Kazançlar: Andy şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Andy Robbins (48 yo)

4.1yrs

Görev süresi

US$7,898,772

Tazminat

Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director at of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Andrew Robbins
President4.1yrsUS$7.90mVeri yok
John Robinson
Chief Scientific Officer3.6yrsUS$2.98m0%
$ 0
Jessica Sachs
Chief Medical Officer5.4yrsUS$3.00m0.0012%
$ 11.6k
John Green
CFO & Principal Accounting Officer4.3yrsUS$2.14mVeri yok
Brad Barnett
Chief Technology Officer4yrsVeri yokVeri yok
Christi Waarich
Senior Director of Investor Relationsno dataVeri yokVeri yok
Evan Kearns
Chief Legal Officer & Corporate Secretary3.5yrsVeri yokVeri yok
Erin Schellhammer
Chief People Officerno dataVeri yokVeri yok
Dana Martin
Senior VP of Medical Affairs & Chief Patient Officerno dataVeri yokVeri yok
Brad Fell
Senior Vice President of Chemistryno dataVeri yokVeri yok
Rachael Easton
VP & Head of Clinical Development2yrsVeri yokVeri yok
Ben Exter
Senior VP and Head of Regulatory & Pharmacovigilanceless than a yearVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: COGT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Andrew Robbins
President4.1yrsUS$7.90mVeri yok
Arlene Morris
Independent Director5.3yrsUS$345.49k0%
$ 0
Matthew Ros
Independent Director5.3yrsUS$336.69k0%
$ 0
Todd Shegog
Independent Director3.8yrsUS$345.80k0%
$ 0
Kwok-Kin Wong
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Karen Jean Ferrante
Independent Director6.8yrsUS$340.37k0%
$ 0
Michael Vasconcelles
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Ryan Corcoran
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Christopher Cain
Independent Director4.3yrsUS$341.36k0%
$ 0
Peter Harwin
Independent Chairman of the Board4.3yrsUS$364.55k0%
$ 0
Srdan Verstovsek
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Sylvia Adams
Member of Scientific Advisory Board1.8yrsVeri yokVeri yok

4.3yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: COGT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).